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ORIGINAL RESEARCH
Effectiveness of lurasidone in schizophrenia or
schizoaffective patients switched from other
antipsychotics: a 6-month, open-label, extension study
Leslie Citrome,1* Peter J. Weiden,2 Joseph P. McEvoy,3 Christoph U. Correll,4
Josephine Cucchiaro,5 Jay Hsu,5 and Antony Loebel5
1 Department of Psychiatry & Behavioral Sciences, New York Medical College, Valhalla, New York, USA
2 Department of Psychiatry, University of Illinois at Chicago, Chicago, Illinois, USA
3 Department of Psychiatry, Georgia Regents University, Augusta, Georgia, USA
4 Department of Psychiatry & Molecular Medicine, Hofstra North Shore – LIJ School of Medicine, Hempstead, New York, USA
5 Sunovion Pharmaceuticals Inc., Fort Lee, New Jersey, USA
Objective. To evaluate the long-term safety and tolerability of lurasidone in schizophrenia and schizoaffective disorder
patients switched to lurasidone.
Method. Patients in this multicenter, 6-month open-label, flexible-dose, extension study had completed a core 6-week
randomized trial in which clinically stable, but symptomatic, outpatients with schizophrenia or schizoaffective
disorder were switched to lurasidone. Patients started the extension study on treatment with the same dose of
lurasidone taken at study endpoint of the 6-week core study; following this, lurasidone was flexibly dosed
(40–120mg/day), if clinically indicated, starting on Day 7 of the extension study. The primary safety endpoints
were the proportion of patients with treatment emergent adverse events (AEs), serious AEs, or who discontinued due
to AEs. Secondary endpoints included metabolic variables and measures of extrapyramidal symptoms and
akathisia, as well as the Positive and Negative Syndrome Scale (PANSS), Clinical Global Impressions-Severity
(CGI-S), and the Calgary Depression Scale for Schizophrenia (CDSS). The study was conducted from August 2010 to
November 2011.
Results. Of the 198 patients who completed the 6-week core study, 149 (75.3%) entered the extension study and 148
received study medication. A total of 98 patients (65.8%) completed the 6-month extension study. Lurasidone 40, 80,
and 120mg were the modal daily doses for 19 (12.8%), 65 (43.9%), and 64 (43.2%) of patients, respectively. Overall
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mean (SD) daily lurasidone dose was 102.0mg (77.1). The most commonly reported AEs were insomnia (13 patients
[8.8%]), nausea (13 patients [8.8%]), akathisia (12 patients [8.1%]), and anxiety (9 patients [6.1%]). A total
of 16 patients (10.8%) had at least one AE leading to discontinuation from the study. Consistent with prior
studies of lurasidone, there was no signal for clinically relevant adverse changes in body weight, lipids, glucose,
insulin, or prolactin. Movement disorder rating scales did not demonstrate meaningful changes. Treatment
failure (defined as any occurrence of discontinuation due to insufficient clinical response, exacerbation of underlying
disease, or AE) was observed for 19 patients (12.8% of patients entering) and median time to treatment failure
was 58 days (95% CI 22–86). The discontinuation rate due to any cause was 50/148 (33.8%), and median time
to discontinuation was 62 days (95% CI 30–75). The mean PANSS total score, mean CGI-S score, and mean
CDSS score decreased consistently from core study baseline across extension visits, indicating an improvement in
overall condition.
Conclusions. In this 6-month, open-label extension study, treatment with lurasidone was generally well-tolerated with
sustained improvement in efficacy measures observed in outpatients with schizophrenia or schizoaffective disorder
who had switched to lurasidone from a broad range of antipsychotic agents.
Received 21 September 2013; Accepted 6 November 2013; First published online 16 December 2013
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Introduction
Many outpatients with schizophrenia or schizoaffective
disorder continue to suffer from persistent symptoms, or
experience side effects associated with their current
maintenance antipsychotic. Treatment strategies
include dose adjustments, addition of adjunctive med-
ications, or allowing the passage of time in the hopes of
achieving further symptom reduction and the diminu-
tion of adverse effects. Another important treatment
consideration is whether or not to change antipsychotic
medications. The substitution of one antipsychotic
agent by another is informally known as ‘‘switching.’’
Based on the above, it is not surprising that switching
between antipsychotic medications commonly occurs in
the routine treatment of schizophrenia, in an effort to
find the optimal regimen for an individual patient.1–3
Switching can be motivated by the desire to improve
efficacy, tolerability, or both.4,5 A number of switch
techniques have been employed in evaluating optimal
approaches to the initiation of the new antipsychotic
and/or the discontinuation of the pre-switch agent.6–9
Despite the appeal of switching antipsychotics, there are
also potential concerns of complications from attempt-
ing a switch, such as symptom exacerbation, insufficient
efficacy, and new tolerability problems emerging from
the ‘‘post-switch’’ medication.
Lurasidone10 is a second-generation antipsychotic
medication that received regulatory approval for the
treatment of adults with schizophrenia in the U.S. in
201011 and in Canada in 2012.12,13 Detailed systematic
reviews of the overall efficacy, tolerability, safety, and place
in therapy of lurasidone can be found elsewhere.14,15
This report is of a 6-month extension to a core
6-week study in which outpatients, who were previously
treated with another first-line antipsychotic, were
successfully switched to lurasidone monotherapy.16
Details of the core study, where patients in a non-acute
phase of illness were randomized to 1 of 3 lurasidone
dosing regimens for the initial 2 weeks of the study and
then flexibly dosed for the subsequent 4 weeks of the
study, can be found elsewhere.16 The primary objective
of the extension study was to evaluate the long-term
safety and tolerability of lurasidone as measured by the
proportions of patients with AEs, serious AEs (SAEs),
and discontinuations due to AEs or SAEs. One of the
secondary objectives was to evaluate the long-term
efficacy of lurasidone.
Method
This multicenter, open-label, 6-month study was con-
ducted at 26 clinical sites in the United States
(ClinicalTrials.gov identifier: NCT01143090). All
patients had completed the 6-week core study, the
details of which can be found elsewhere.16 All patients
received open-label lurasidone. The study was reviewed and
approved by an institutional review board at each study
center, and the trial was conducted in accordance with
Good Clinical Practice as required by the International
Conference on Harmonization guidelines. Compliance
with these requirements also constitutes conformity with
the ethical principles of the Declaration of Helsinki.
Participants
Key inclusion criteria for the 6-week lurasidone switch
study that immediately preceded the extension study
were that patients had to be adults with either
schizophrenia or schizoaffective disorder who had at
least a partial response to, and were stable on, a first-
line antipsychotic at a dose consistent with product
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labeling. Patients who were unstable (eg, recent
hospitalization) or known to be treatment-resistant
(eg, prior treatment with clozapine) were excluded.
Patients also had to have a clinically relevant basis to
change antipsychotics such that clinically significant
efficacy or tolerability concerns had to be present on
their current medication despite efforts at optimization.
In order to enroll in the extension study, patients
were required to have completed the 6-week core study,
be judged suitable for participation in the extension
trial and able to comply with the protocol in the opinion
of the investigator, and to provide informed consent.
The remaining study eligibility requirements were
similar to that of the preceding core study.16
Interventions
All patients started the extension study on treatment
with the same dose of lurasidone taken at study
endpoint of the 6-week core study; following this,
lurasidone was flexibly dosed (40–120mg/day), if
clinically indicated, starting on Day 7 of the extension
study. When made, dose adjustments occurred at weekly
intervals and in increments/decrements of 40mg/day,
based on investigator judgment in order to optimize
efficacy and tolerability. The study drug was taken once
daily in the evening with food or within 30minutes after
eating. The study drug, packaged in blister cards, was
dispensed by the designated site study staff. Patients
took the study drug at home following the directions
provided to them by the study site.
Consistent with the preceding core study, medica-
tions used to treat movement disorders were not given
prophylactically, but agents for emerging or worsening
parkinsonism or akathisia were permitted. Concomitant use
of agents for the treatment of anxiety symptoms, agitation,
or insomnia was permitted during the study at the
discretion of the investigator, as in the core study.16 Patients
may have initiated and/or continued treatment with
concurrent lithium, divalproex, lamotrigine, or antidepres-
sants during the course of the study. Patients could
continue to participate in ongoing psychotherapeutic and
psychosocial interventions during the course of this trial.
Compliance was monitored closely and determined at
each visit. Patients were instructed to bring all used
bottles and unused study drug with them to each visit.
Patients who missed more than 25% of the scheduled
doses or who took more than 125% of the scheduled
doses were considered noncompliant.
Outcomes
The primary endpoints were the proportion of patients
with adverse events (AEs), serious AEs (SAEs), or who
discontinued due to AEs. AEs were defined as events
with onset on or after the first study drug dose in the
extension study until 7 days after the last dose in the
extension study. AEs that occurred during the core
study are reported elsewhere.16 The secondary safety
endpoints included the mean change from both core and
extension study baselines in weight, lipids, and glycemic
control, Simpson–Angus Scale (SAS),17 Barnes Akathisia
Rating Scale (BARS),18 and Abnormal Involuntary
Movement Scale (AIMS).19 The secondary efficacy
endpoints included the mean change from both core
and extension study baselines in the Positive and
Negative Syndrome Scale (PANSS)20 total scores,
Clinical Global Impression Severity of Illness (CGI-S)21
scores, and Calgary Depression Scale for Schizophrenia
(CDSS)22 scores. Additional assessments included were
the Columbia-Suicide Severity Rating Scale (C-SSRS)
(designed for the assessment of suicidal ideation and
behavior in clinical and research settings),23 Health
Services Utilization Questionnaire (HSUQ) (designed to
capture types and quantities of health and social services
used by an individual),24 Personal Evaluation of Transi-
tions in Treatment (PETiT) (designed to capture aspects
of subjective responses to, and tolerability of, antipsy-
chotic drugs, treatment adherence, and impact of
antipsychotic drug therapy on the quality of life of
individuals treated for schizophrenia),25 Short Form-12
Health Survey (SF-12) (self-rating scale designed
to assess overall physical and emotional health and
how well a person is able to accomplish his/her usual
activities),26 and Medication Satisfaction Questionnaire
(MSQ) (a single-item questionnaire that evaluates
satisfaction with antipsychotic medication).27 In addition,
physical examinations, ECGs, and routine fasting clinical
laboratory measures were obtained. Regular study visits
were scheduled at intervals of 1 month, with weekly
telephone contacts between visits. A post-treatment
follow-up visit occurred 1 week after the last dose of
study drug to assess any post-treatment discontinuation
AEs. At the follow-up visit, the patients were instructed
to contact the study site if AEs were experienced in the
7 days following the last visit. If the patient was unable
to make the visit in person, a telephone contact was
made to assess any post-treatment discontinuation AEs.
Statistical analysis
The extension study baseline was defined as the last
non-missing assessment during the treatment period of
the core study. The ‘‘safety population’’ consisted of all
patients who signed informed consent and received at
least one dose of study drug in the extension study.
The ‘‘intent-to-treat population’’ (ITT) consisted of all
randomized patients who signed informed consent,
received at least 1 dose of study drug in the core study,
and had a core study baseline and at least 1 extension
study efficacy measurement from the same scale. If a
332 L. CITROME ET AL.
patient had only a core study baseline but no extension
study values, all change-from-baseline values would be
missing, and the patient would be effectively excluded
from the ITT analysis.
No hypothesis testing was performed for the primary
safety endpoints for this study; only descriptive statistics
were compiled. Summaries of change from baseline in
all continuous efficacy and safety measures included
change from core study baseline and change from
extension study baseline. For secondary endpoints,
change from core study baseline and from extension
study baseline in PANSS total scores, CGI-S, and CDSS
were tested with a 1-sample t-test of the least squares
(LS) means. Least squares means were provided from an
analysis of covariance (ANCOVA) with treatment and
pooled center as fixed factors and baseline value as a
covariate. The same pooled sites created in the core
study were used in this study.
Additional descriptive statistics were compiled for
both time to discontinuation due to treatment failure
and time to any discontinuation. ‘‘Treatment failure’’
was defined as any occurrence of discontinuation due to
insufficient clinical response, exacerbation of under-
lying disease, or AE, and was the primary outcome
measure of the core study.16 Time to discontinuation
due to treatment failure and time to any discontinuation
were compiled starting from the first extension study
dose. Kaplan–Meier (KM) plots were created for both
time to discontinuation due to treatment failure and
time to any discontinuation. Patients who did not
discontinue were considered censored in the KM plots.
Results
Of the 198 patients who completed the core 6-week
study, 149 (75.3%) entered the extension study. The first
patient was enrolled on August 10, 2010, and the last
patient completed the study on November 28, 2011.
A total of 98 patients (65.8%) completed the 6-month
study. A total of 51 patients (34.2%) discontinued from
the study: 18 (12.1%) withdrew consent, 17 (11.4%)
discontinued due to AEs (of which 9 [6.0%] had AEs
associated with exacerbation of underlying disease),
9 (6.0%) were lost to follow-up, 2 (1.3%) due to
insufficient clinical response, 2 (1.3%) due to protocol
violations, 1 (0.7%) failed to meet inclusion/exclusion
criteria, 1 (0.7%) due to noncompliance with study
drug, and 1 (0.7%) due to an administrative reason.
Excluded from the safety and efficacy analyses was
1 patient who did not receive study medication in the
extension study. See Table 1 for patient demographics
and baseline clinical characteristics of the study
population.
Lurasidone 40, 80, and 120mg were the modal daily
doses for 19 (12.8%), 65 (43.9%), and 64 (43.2%) of
patients, respectively. The overall mean (SD) daily
lurasidone dose was 102.0 (77.1) mg, and the median
daily dose was 89mg.The mean (SD) extent of exposure
was 134.4 (61.8) days, and the median extent of
exposure was 170 days. Noncompliance with study
dosing was reported for 27 (18.2%) of patients, with 3
(2.0%) missing .25% of scheduled doses and 24
(16.2%) classified as taking .125% of scheduled doses.
Patients who did not return their blister cards at
monthly study visits were conservatively regarded as
taking .125% of scheduled doses; we note that some
subjects may have had difficulty returning cards due to
illness-related factors.
Safety and tolerability outcomes
A total of 98 patients (66.2%) had at least 1 AE. The
incidences of the most commonly encountered AEs, as
defined by frequency $ 2% among all patients, are
noted in Table 2. The most commonly reported AEs
were insomnia (13 patients [8.8%]), nausea (13 patients
[8.8%]), akathisia (12 patients [8.1%]), and anxiety
(9 patients [6.1%]). Most patients had only mild or
moderate AEs. Severe AEs were uncommon; these
events were reported by 10 patients (6.8%): 2 patients
(1.4%) had severe dysphoria, and no other severe AE
was reported by more than 1 subject. There were no
deaths. Psychiatric hospitalizations occurred in 7 (4.7%)
of patients.
The most common extrapyramidal symptom AEs
were tremor (3 patients [2.0%]), dystonia (2 patients
[1.4%]), and parkinsonism (2 patients [1.4%]). Drool-
ing, extrapyramidal disorder, and trismus were each
reported by 1 subject. The most common cardiovascu-
lar/metabolic AEs were hypertension (5 patients
[3.4%]) and hyperlipidemia (3 patients [2.0%]). Three
patients (2.0%) had a weight increase reported as an AE,
and 2 patients (1.4%) had a weight decrease reported as
an AE (we note that weight change reported as an AE by
the investigator is complementary to the objectively
collected quantitative weight data). Blood pressure
increase and hypercholesterolemia were each reported
by 1 subject. Sedation was reported by 4 patients (2.7%),
and somnolence was reported by 1 patient (0.7%).
There were 8 patients (5.4%) with 11 treatment-
emergent SAEs. Six patients had 1 SAE, 1 patient had 2
SAEs, and 1 patient had 3 SAEs. The most common
treatment-emergent SAEs were exacerbations of schi-
zoaffective disorder (3 patients [2.0%]) or schizophrenia
(2 patients [1.4%]) and suicidal ideation (2 patients
[1.4%]). Bipolar I disorder, paranoia, and homicidal
ideation were each reported by 1 subject.
Discontinuation from the study because of an AE
occurred in 16 patients (10.8%). The most common AEs
leading to discontinuation were schizoaffective disorder
LURASIDONE 6-MONTH EXTENSION STUDY 333
(4 patients [2.7%]) and vomiting (2 patients [1.4%]).
No other individual AE led to the discontinuation of
more than 1 subject.
No clinically relevant changes were observed for
changes from core study and extension study baselines
to last observation carried forward (LOCF) endpoint in
weight, body mass index, waist circumference, lipids,
glucose, HbA1c, insulin, C-reactive protein, or prolac-
tin. Figure 1 illustrates the median change in weight,
total cholesterol, triglycerides, and glucose from core
study baseline.
A larger proportion of patients experienced $ 7%
weight loss from baseline compared to$ 7% weight gain
over the 6-month observation period (Table 3). The
proportions differed depending on the antipsychotic
received prior to receiving lurasidone in the core study.
From core study baseline to extension LOCF endpoint,
the percentage of subjects with $ 7% weight loss vs $
7% weight gain were 3.2% vs 6.5% for subjects who had
received aripiprazole, 23.1% vs 7.7% for olanzapine,
16.7% vs 13.3% for quetiapine, 22.2% vs 11.1% for
risperidone, and 16.7% vs 11.1% for ziprasidone. There
were absolute mean weight decreases from core study
baseline to month 6 for all but the risperidone pre-
switch antipsychotic medication subgroup (see Table 4).
The largest mean decrease was 21.0 kg (ziprasidone
TABLE 1. Patient demographics and baseline clinical characteristics (safety population)
Characteristic Lurasidone overall (N5 148)
Gender, n (%)a
Male 93 (62.8)
Female 55 (37.2)
Race, n (%)
Black or African American 95 (64.2)
White 47 (31.8)
Other 6 (4.1)
Ethnicity, n (%)
Hispanic or Latino 13 (8.8)
Not Hispanic or Latino 135 (91.2)
Age (years)
Mean (SD) 42.8 (11.1)
Mean age (SD) at initial onset of schizophrenia or schizoaffective disorder (years) 24.3 (9.5)
DSM-IV diagnosis
Schizophrenia (295.10, 295.30, 295.60, 295.90) disorganized type 90 (60.8)
Schizoaffective disorder (295.70) 58 (39.2)
Prior number of hospitalizations for schizophrenia or schizoaffective disorder
0 31 (20.9)
1 20 (13.5)
2 22 (14.9)
3 20 (13.5)
4 or more 55 (37.2)
Mean Positive and Negative Syndrome Scale total score (SD) at core study baselinea 67.9 (13.9)
Mean Positive and Negative Syndrome Scale total score (SD) at extension study baselinea 60.1 (13.6)
Mean Clinical Global Impression Severity score (SD) at core study baselinea 3.62 (0.53)
Mean Clinical Global Impression Severity score (SD) at extension study baselinea 3.21 (0.62)
Mean Calgary Depression Scale for Schizophrenia total score (SD) at core study baselinea 3.6 (3.8)
Mean Calgary Depression Scale for Schizophrenia total score (SD) at extension study baselinea 2.1 (3.1)
Mean weight (SD) (kg) at core study baseline 91.9 (21.5)
Mean weight (SD) (kg) at extension study baseline 91.7 (21.3)
Pre-switch antipsychotic agent, n (%)
Aripiprazole 32 (21.6)
Quetiapine 31 (20.9)
Risperidone 29 (19.6)
Ziprasidone 18 (12.2)
Olanzapine 13 (8.8)
Paliperidone 7 (4.7)
Iloperidone 2 (1.4)
Asenapine 2 (1.4)
First-generation antipsychoticb 14 (9.5)
aIntent-to-treat population (N5 144).
bHaloperidol (n5 5), perphenazine (n5 4), chlorpromazine (n5 2), fluphenazine (n5 2), thiothixene (n5 1).
Abbreviations: DSM-IV5 Diagnostic and Statistical Manual of Mental Disorders, fourth edition; SD5 standard deviation.
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subgroup). Change in lipid and glucose variables from
the core study baseline to month 6 for patients who
received quetiapine, olanzapine, aripiprazole, risperi-
done, and ziprasidone pre-switch are described in Table
4. From core study baseline to extension study LOCF
endpoint, most patients had metabolic variables that did
not shift categories (ie, stayed in same category: normal
to normal, low to low, or high to high). Among the 72
patients with high LDL cholesterol values at core study
baseline, 22 patients (30.6%) had normal LDL cholesterol
values at extension study LOCF endpoint. Among the
11 patients with high glucose values at core study
baseline, 6 patients (54.5%) had normal glucose values
at extension study LOCF endpoint.
The largest mean decreases in prolactin at month 6
were seen for patients previously treated with risperidone
(27.5 ng/mL [SD 17.0 ng/mL], median –5.8 ng/mL),
and the largest mean increases in prolactin at month 6
were seen for patients previously treated with quetiapine
(4.8 ng/mL [SD 13.7 ng/mL], median 2.0 ng/mL).
Generally, larger median changes in prolactin were
observed in females than males for each pre-switch
antipsychotic medication. Overall, prolactin results for
most patients did not shift categories from the core
study baseline to extension study LOCF endpoint. Four
patients (2.9%), 3 men and 1 woman, had normal to
high shifts in prolactin. Other patients with increases in
prolactin included 6 patients (4.3%) who shifted from
low to normal and 2 patients (1.4%) who shifted from
low to high. However, high to normal shifts were
observed in 13 patients (9.4%), 7 women and 6 men.
There were no clinically meaningful changes at
month 6 in any ECG or vital sign parameter, as assessed
relative to core study baseline or extension study baseline.
TABLE 2. Adverse events with an incidence $ 2% (safety
population)
Adverse event
Lurasidone overall
(N5 148)
n (%)
Gastrointestinal disorders 34(23.0)
Nausea 13 (8.8)
Dry mouth 7 (4.7)
Vomiting 7 (4.7)
Constipation 4 (2.7)
Abdominal pain upper 3 (2.0)
Diarrhea 3 (2.0)
Toothache 3 (2.0)
General disorders and administration site conditions 6(4.1)
Fatigue 3 (2.0)
Infections and infestations 17(11.5)
Upper respiratory tract infection 4 (2.7)
Influenza 3 (2.0)
Injury, poisoning, and procedural complications 11(7.4)
Contusion 4 (2.7)
Investigations 12(8.1)
Blood creatine phosphokinase increased 4 (2.7)
Weight increased 3 (2.0)
Metabolism and nutrition disorders 8(5.4)
Decreased appetite 3 (2.0)
Hyperlipidemia 3 (2.0)
Musculoskeletal and connective tissue disorders 17(11.5)
Musculoskeletal pain 3 (2.0)
Neck pain 3 (2.0)
Nervous system disorders 31(20.9)
Akathisia 12 (8.1)
Dizziness 4 (2.7)
Headache 4 (2.7)
Sedation 4 (2.7)
Dyskinesia 3 (2.0)
Tremor 3 (2.0)
Psychiatric disorders 42(28.4)
Insomnia 13 (8.8)
Anxiety 9 (6.1)
Schizoaffective disorder 5 (3.4)
Paranoia 4 (2.7)
Agitation 3 (2.0)
Depression 3 (2.0)
Depressive symptom 3 (2.0)
Hallucination, auditory 3 (2.0)
Suicidal ideation 3 (2.0)
Vascular disorders 7(4.7)
Hypertension 5 (3.4)
FIGURE 1. Median change from core study baseline to LOCF endpoint on
metabolic variables. The number of patients available for assessment
ranged from 117 for triglycerides and glucose to 144 for weight. Median
changes from extension study baseline to LOCF endpoint were similarly
small (weight 20.7 kg, total cholesterol 22.0 mg/dL, triglycerides
6.0 mg/dL, glucose 2.0 mg/dL).
TABLE 3. Changes in weight $ 7% from core and extension
study baselines to LOCF endpoint (N5 144)
From core study
baseline
From extension study
baseline
Weight gain $ 7%, n (%) 23 (16.0%) 14 (9.7%)
Weight loss $ 7%, n (%) 27 (18.8%) 17 (11.8%)
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There were no patients with an ECG QTc (Fridericia)
interval. 500ms, or an increase from core study baseline
in QTc . 60ms, at any time during the study.
Median and mean SAS, BARS, and AIMS scores did
not demonstrate meaningful changes from either core
or extension study baselines (median changes were 0).
BARS global scores remained unchanged between core
study baseline and month 6 of the extension study for
most of the patients (82.7%); a total of 12.2% of
patients improved with respect to akathisia and 5.1% of
patients worsened. Results were similar relative to
extension study baseline.
Few patients had worsening in the C-SSRS relative to
core study baseline. Four patients (2.8%) had worsening
of their suicidal ideation (ie, more severe than at baseline).
A total of 7 patients (4.9%) had emergence of suicidality
(ideation and/or behavior). There were no suicide
attempts/completions.
Efficacy outcomes
A summary of PANSS, CGI-S, and CDSS outcomes are
presented in Table 5. The mean PANSS total score,
mean CGI-S score, and mean CDSS score decreased
consistently from core study baseline across extension
visits, indicating an improvement in overall condition.
PANSS total score results were generally similar across
subgroups of gender, age group, race, and ethnicity; any
differences were not considered clinically meaningful.
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TABLE 5. Positive and Negative Syndrome Scale, Clinical Global
Impressions–Severity, and Calgary Depression Scale for
Schizophrenia – mean change (standard deviation) from core
and extension study baselines to LOCF endpoint, LS mean
(standard error), and within-group p-value
Rating scalea
Lurasidone intent-to-treat population
(N5 144)
From core study
baseline
From extension study
baseline
Positive and Negative Syndrome Scale
Mean change (standard deviation) –8.2 (12.6) –0.4 (9.4)
LS mean (standard error) –8.8 (1.1) –1.5 (0.9)
Within-group p-value , 0.0001 0.0836
Clinical Global Impressions-Severity
Mean change (standard deviation) –0.39 (0.85) 0.02 (0.63)
LS mean (standard error) –0.4 (0.1) 0.0 (0.1)
Within-group p-value , 0.0001 0.6885
Calgary Depression Scale for Schizophrenia
Mean change (standard deviation) –1.2 (4.3) 0.3 (3.3)
LS mean (standard error) –1.3 (0.3) 0.2 (0.3)
Within-group p-value 0.0002 0.6084
aSee Table 1 for baseline values.
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The HSUQ responses indicated that in addition to the
normal clinical visits, 17.4% of patients, on average, saw
‘‘a doctor or other healthcare provider for psychiatric
problems or alcohol or drug use’’ per month (range:
11.0% to 20.5% across extension visits). Few patients
visited an emergency room for an emotional/psychiatric
problem (mean 0.8% per month [range 0% to 3.8%]) or for
a medical problem (mean 2.1% per month [1.5% to 3.8%]).
Few patients were in contact with the criminal justice
system (mean: 1.8% per month [0% to 3.7%]).
The PETiT inventory demonstrated a positive sub-
jective response to treatment with a mean change from
core study baseline to month 6 of 5.1 (SD 7.2) and 2.6
(SD 8.8) at extension study LOCF endpoint. Relative to
the extension study baseline, however, there were
decreases for the PETiT scores: 20.9 (SD 6.6) at month
6 and 21.9 (SD 7.2) at extension study LOCF endpoint.
The SF-12 scores showed numerical increases
(improvement) relative to core study baseline for all
measures (physical functioning, role physical, bodily pain,
general health, vitality, social functioning, role emotional,
and mental health) at month 6. Overall changes were small
as noted by a median change of 0 from either core study
baseline or extension study baseline to extension LOCF for
all the components of the SF-12.
The MSQ mean score at core study baseline was 4.2
(SD 1.5) (between MSQ questionnaire responses
45 ‘‘neither dissatisfied nor satisfied’’ and 55 ‘‘somewhat
satisfied’’). At month 6, the mean score had increased by
1.4 (SD 1.9) (between MSQ questionnaire responses
55 ‘‘somewhat satisfied’’ and 65 ‘‘very satisfied’’).
Relative to the extension study baseline, a slight
decrease was observed for MSQ mean change; however,
median change at extension LOCF was 0.
Effectiveness outcomes
Treatment failure (discontinuation due to insufficient
clinical response, exacerbation of underlying disease,
or AE) was observed for 19 patients (12.8%), of which
2 (1.4%) were for insufficient clinical response and
17 (11.5%) for AEs including exacerbation of underlying
disease. Median time to treatment failure was 58 days
(95% CI 22–86) (Figure 1). The discontinuation rate for
any reason was 50/148 (33.8%), and median time to
discontinuation was 62 days (95% CI 30–75) (Figure 2).
Discussion
This was a 6-month, open-label extension to a study
where non-acute patients who met Diagnostic and
Statistical Manual of Mental Disorders, 4th edition,
text revision (DSM-IV-TR) criteria for schizophrenia or
schizoaffective disorder were switched to lurasidone due
to insufficient efficacy and/or safety/tolerability concerns.
The overall safety profile was consistent with findings
from previous studies, and no new safety concerns were
identified. The most commonly reported AEs were
insomnia (8.8%), nausea (8.8%), akathisia (8.1%), and
anxiety (6.1%). There were no signals to indicate
clinically relevant alterations in metabolic variables
associated with lurasidone treatment. Greater propor-
tions of subjects experienced weight loss $ 7% from
baseline than the equivalent amount of weight gain
(Table 3). In terms of efficacy, there were consistent and
statistically significant decreases in mean PANSS total
score from the core study baseline to all extension visits,
indicating consistent improvement at each month.
Similar findings were observed on the CGI-S and CDSS.
Positive subjective responses to treatment with lurasi-
done were generally observed in PETiT scores, SF-12,
and MSQ changes relative to the core study baseline,
denoting the acceptability of longer-term lurasidone
treatment after switching from other agents. Improvement
in these assessments, taken together, may also suggest
the potential for enhanced adherence to treatment with
FIGURE 2A. Time to treatment failure (Kaplan–Meier). Treatment failure is
defined as discontinuation due to insufficient clinical response,
exacerbation of underlying disease, or an adverse event.
FIGURE 2B. Time to discontinuation for any cause (Kaplan–Meier).
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lurasidone. Few patients required emergency room visits,
or were in contact with the criminal justice system, as
measured by the HSUQ. The overall incidence of
discontinuation due to treatment failure in this study
was low (12.8%), with a median time to treatment
failure of 58 days.
Generalizability of the study results is enhanced by
the inclusion of patients with schizoaffective disorder
who comprised about 39% of the sample. The study was
conducted entirely in the U.S., and the racial/ethnic
distribution of subjects was similar to that in the
Phase II schizophrenia trials of lurasidone, which were
also conducted entirely in the U.S. In those studies,
black/African Americans comprised the majority of
study participants.28,29
The current product label10 provides for a dosing
range for lurasidone of 40–160mg/d. In our study,
investigators were free to dose flexibly within the range
of 40–120mg/day according to the perceived tolerability
and efficacy of lurasidone experienced by the individual
subject. In the extension study, almost equal numbers of
patients received a modal dose of 80 or 120mg/day
(43.9% and 43.2% of patients, respectively), with only
12.8% receiving 40mg/day. In the core study,16
lurasidone 40, 80, and 120mg/d were the modal daily
doses for 21.3%, 49.6%, and 29.2% of subjects,
respectively. At core study baseline, subjects were
randomized to 3 different lurasidone dose initiation
groups, with flexible dosing permitted from week 2 to
the week 6 core study endpoint. In the current
extension study, all subjects were flexibly dosed, starting
at the dose achieved at core study endpoint. No
comparisons among the initially randomized groups in
the core study were performed in this extension study.
The safety and tolerability results reported here are
consistent with data from other open-label lurasidone
extension studies with durations of 6 months30 and 22
months,31 and from 12-month double-blind studies
comparing lurasidone with quetiapine extended-
release32 and lurasidone with risperidone.33 A common
finding that arises is lurasidone’s relatively benign
weight34,35 and metabolic35 profile, including the poten-
tial for normalization of weight and lipid parameters.30
This has long-term implications for morbidity and
mortality when treating patients with schizophrenia, and
can make the choice of lurasidone compelling.
Several study limitations should be noted. Although
the extension study was of 6 months duration, it may
still have been too short to fully characterize lurasi-
done’s long-term safety profile. Moreover, the open-
label design and lack of a parallel control group limits
interpretability. As with any extension study, there may
be a decrease in apparent incidence of some AEs if these
AEs had led to study discontinuation from the core study
or if they had been transient or successfully treated.
Conclusions
In this 6-month, open-label study, treatment with
lurasidone continued to be generally well-tolerated in
patients with schizophrenia or schizoaffective disorder
who had switched to lurasidone from a broad range
of antipsychotic agents. The most commonly reported
AEs were insomnia, nausea, akathisia, and anxiety.
There was no signal for clinically relevant adverse
changes in body weight, lipids, glucose, insulin, or
prolactin. Patients were able to maintain clinical improve-
ment (as assessed by PANSS, CGI-S, and CDSS) over 6
months of follow up. Positive subjective responses to
treatment with lurasidone were also observed (as assessed
by PETiT scores, SF-12, and MSQ).
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